Skip to main content

Table 7 Demographic and clinical characteristics for the different genotypes of rs4353135 in UC patients

From: Genotype–phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients

 

rs4353135

TT

rs4353135

GT

rs4353135

GG

p value (Fisher or Kruskal–Wallis)

Gender

 Male (n = 369)

 Female (n = 321)

169 (53.3%)

148 (46.7%)

165 (55.2%)

134 (44.8%)

35 (47.5%)

39 (52.7%)

0.474

Age at diagnosis [years]

 Median, q25q75,

 Minmax

27.4, 19.7–38.4,

3.2–79.6

28.7, 20.4–38.4,

2.9–78.1

29.3, 19.2–42.6,

3.9–72.1

0.628

Disease duration [years]

 Median, q25q75,

 Minmax

10.9, 6.9–18.4,

0.3–49.5

11.5, 6.9–17.6,

0.2–48.7

13.1, 6.9–22.5,

1.0–45.3

0.580

Complications*

 No (n = 286)

 Yes (n = 404)

135 (42.6%)

182 (57.4%)

125 (41.8%)

174 (58.2%)

26 (35.1%)

48 (64.9%)

0.507

MTWAI**—maximal value throughout follow-up

 Median, q25q75,

 Minmax

4, 2–9,

0–19

5, 2–9,

0–18

4, 2–7,

0–14

0.129

Reported flare*

 No (n = 284)

 Yes (n = 406)

121 (38.2%)

196 (61.8%)

130 (43.5%)

169 (56.5%)

33 (44.6%)

41 (55.4%)

0.329

Flare possibly or highly related to (focus on yes):

 NSAIDs

 Antibiotics

 GI tract infection

 Other infection

 Treatment decr./disc

 Other medication

11 (5.6%)

4 (2.0%)

32 (16.3%)

23 (11.7%)

50 (25.5%)

4 (2.0%)

11 (6.5%)

4 (2.4%)

34 (20.1%)

11 (6.5%)

41 (24.3%)

9 (5.3%)

1 (2.4%)

0 (0%)

8 (19.5%)

5 (12.2%)

7 (17.1%)

1 (2.4%)

0.705

1.000

0.632

0.168

0.543

0.219

Flare management (focus on the yes):

 Hospitalization

 Ambulatory

 Surgery

 Drug therapy

24 (12.2%)

67 (34.2%)

8 (4.1%)

178 (90.8%)

20 (11.8%)

30 (17.8%)

10 (5.9%)

150 (88.8%)

2 (4.9%)

7 (17.1%)

1 (2.4%)

40 (97.6%)

0.443

0.001

0.692

0.248

Focus on the hospitalizations:

 Total days of hosp.

 Median, q25q75,

 Minmax

6.5, 2.5–18.5,

0–90

0, 0–7,

0–41

3, 0–6,

0–6

0.038

  1. Bold indicates a significant p-value (p < 0.05)